74 related articles for article (PubMed ID: 15498602)
1. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses.
Wu JJ; Huang DB; Tyring SK
Antiviral Res; 2004 Nov; 64(2):79-83. PubMed ID: 15498602
[TBL] [Abstract][Full Text] [Related]
2. Resiquimod, a topical drug for viral skin lesions and skin cancer.
Meyer T; Surber C; French LE; Stockfleth E
Expert Opin Investig Drugs; 2013 Jan; 22(1):149-59. PubMed ID: 23205468
[TBL] [Abstract][Full Text] [Related]
3. The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation.
Hackstein H; Knoche A; Nockher A; Poeling J; Kubin T; Jurk M; Vollmer J; Bein G
Cell Immunol; 2011; 271(2):401-12. PubMed ID: 21889130
[TBL] [Abstract][Full Text] [Related]
4. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.
Rodell CB; Arlauckas SP; Cuccarese MF; Garris CS; Li R; Ahmed MS; Kohler RH; Pittet MJ; Weissleder R
Nat Biomed Eng; 2018 Aug; 2(8):578-588. PubMed ID: 31015631
[TBL] [Abstract][Full Text] [Related]
5. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.
Rook AH; Gelfand JM; Wysocka M; Troxel AB; Benoit B; Surber C; Elenitsas R; Buchanan MA; Leahy DS; Watanabe R; Kirsch IR; Kim EJ; Clark RA
Blood; 2015 Sep; 126(12):1452-61. PubMed ID: 26228486
[TBL] [Abstract][Full Text] [Related]
6. Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors.
Anfray C; Varela CF; Ummarino A; Maeda A; Sironi M; Gandoy S; Brea J; Loza MI; León S; Calvo A; Correa J; Fernandez-Megia E; Alonso MJ; Allavena P; Crecente-Campo J; Andón FT
Front Immunol; 2023; 14():1334800. PubMed ID: 38259462
[TBL] [Abstract][Full Text] [Related]
7. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.
Chakraborty S; Ye J; Wang H; Sun M; Zhang Y; Sang X; Zhuang Z
Front Immunol; 2023; 14():1227833. PubMed ID: 37936697
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.
Uher O; Hadrava Vanova K; Lencova R; Frejlachova A; Wang H; Zhuang Z; Zenka J; Pacak K
Front Endocrinol (Lausanne); 2023; 14():1030412. PubMed ID: 37342258
[TBL] [Abstract][Full Text] [Related]
9. Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists.
Andón FT; Leon S; Ummarino A; Redin E; Allavena P; Serrano D; Anfray C; Calvo A
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884895
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell.
Girkin JLN; Maltby S; Bartlett NW
Eur Respir Rev; 2022 Jun; 31(164):. PubMed ID: 35508333
[TBL] [Abstract][Full Text] [Related]
11. Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy.
Uher O; Huynh TT; Zhu B; Horn LA; Caisova V; Hadrava Vanova K; Medina R; Wang H; Palena C; Chmelar J; Zhuang Z; Zenka J; Pacak K
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439097
[TBL] [Abstract][Full Text] [Related]
12. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.
Bhagchandani S; Johnson JA; Irvine DJ
Adv Drug Deliv Rev; 2021 Aug; 175():113803. PubMed ID: 34058283
[TBL] [Abstract][Full Text] [Related]
13. Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma.
Lookian PP; Zhao D; Medina R; Wang H; Zenka J; Gilbert MR; Pacak K; Zhuang Z
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810617
[TBL] [Abstract][Full Text] [Related]
14. Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA).
Medina R; Wang H; Caisová V; Cui J; Indig IH; Uher O; Ye J; Nwankwo A; Sanchez V; Wu T; Nduom E; Heiss J; Gilbert MR; Terabe M; Ho W; Zenka J; Pacak K; Zhuang Z
Adv Ther (Weinh); 2020 Sep; 3(9):. PubMed ID: 33709018
[TBL] [Abstract][Full Text] [Related]
15. R848 Is Involved in the Antibacterial Immune Response of Golden Pompano (
Zhou Y; Chen X; Cao Z; Li J; Long H; Wu Y; Zhang Z; Sun Y
Front Immunol; 2020; 11():617522. PubMed ID: 33537035
[TBL] [Abstract][Full Text] [Related]
16. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.
Patinote C; Karroum NB; Moarbess G; Cirnat N; Kassab I; Bonnet PA; Deleuze-Masquéfa C
Eur J Med Chem; 2020 May; 193():112238. PubMed ID: 32203790
[TBL] [Abstract][Full Text] [Related]
17. Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant-Antigen Codelivery.
Wang ZB; Xu J
Vaccines (Basel); 2020 Mar; 8(1):. PubMed ID: 32183209
[TBL] [Abstract][Full Text] [Related]
18. Matrine alleviates imiquimod-induced psoriasiform dermatitis in BALB/c mice via dendritic cell regulation.
Li N; Zhao J; Di T; Meng Y; Wang M; Li X; Liu Z; Zhai C; Zhang L; Ma C; Wang Y; Li P
Int J Clin Exp Pathol; 2018; 11(11):5232-5240. PubMed ID: 31949603
[TBL] [Abstract][Full Text] [Related]
19. The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40.
Caisova V; Li L; Gupta G; Jochmanova I; Jha A; Uher O; Huynh TT; Miettinen M; Pang Y; Abunimer L; Niu G; Chen X; Ghayee HK; Taïeb D; Zhuang Z; Zenka J; Pacak K
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31083581
[TBL] [Abstract][Full Text] [Related]
20. Differential gene expression following TLR stimulation in rag1-/- mutant zebrafish tissues and morphological descriptions of lymphocyte-like cell populations.
Muire PJ; Hanson LA; Wills R; Petrie-Hanson L
PLoS One; 2017; 12(9):e0184077. PubMed ID: 28910320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
